CA2417646A1 - Topical gel delivery system - Google Patents
Topical gel delivery system Download PDFInfo
- Publication number
- CA2417646A1 CA2417646A1 CA002417646A CA2417646A CA2417646A1 CA 2417646 A1 CA2417646 A1 CA 2417646A1 CA 002417646 A CA002417646 A CA 002417646A CA 2417646 A CA2417646 A CA 2417646A CA 2417646 A1 CA2417646 A1 CA 2417646A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- water
- treating
- disorder
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Abstract
A topical aqueous gel composition is provided that has a viscosity of less than about 15,000 cP and a pH of about 3.0 to 9.0 for treating a skin disorder in a human subject. The composition consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such a disorder, (b) a hydrophilic pharmaceutically-acceptable, polymer material such as a lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, (f) water, and (g) optionally an oil phase component and a suitable surfactant. The composition is useful for treating an inflammatory skin disorder, acne, or rosacea. The low viscosity composition has an advantage of being administered more accurately when combined with a container that administers the composition as drops.
Claims (6)
1. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which composition consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a hydrophilic, pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
2. The composition of Claim 1, wherein the compound is an antibiotic, imidazole, retinoid, corticosteroid, or a non-steroidal anti-inflammatory drug (NSAm).
3. The composition of Claim 2, wherein the compound is an antibiotic alone or in combination with a corticosteroid or a retinoid.
4. The composition of Claim 3, wherein the compound is an antibiotic alone.
5. The composition of Claim 4, wherein the antibiotic is clindamycin phosphate.
6. The composition of Claim 5 having a pH of about 4.0 to 7.0, which composition consists essentially of (a) about 0.5% to about 2.0% w/w clindamycin phosphate, (b) about 0.1% to about 0.4% w/w of the polymer, (c) the base to adjust pH, (d) about 15.0% to about 25.0% w/w of a water miscible solvent, (e) less than about 0.2% w/w of a preservative, and (f) QSAD purified water to 100% w/w.
32.
20. The composition of Claim 19 having a pH of about 4.0 to 7.0, which composition consists essentially of (a) about 0.01% to about 0.1% w/w desonide, (b) about 0.1% to about 0.4% w/w of the polymer, (d) about 3.0% to about 10% w/w of a water miscible solvent, (e) less than about 0.25% w/w of a preservative, and (f) QSAD purified water to 100% w/w.
21. The composition of Claim 19 having a pH of about 5.0 to 6.0, which composition consists essentially of:
(a) about 0.025 to about 0.05% w/w desonide, (b) about 0.3% w/w of the polymer, (c) the base to adjust pH, (d) about 5% w/w propylene glycol, (e) about 0.2 - about 0.25% w/w methylparaben and propylparaben, and (f) QSAD purified water to 100% w/w.
22. The composition of Claim 1 in combination with a container that accurately administers a portion of the composition for topical administration to a patient.
23. The composition of Claim 22 in combination with labeling instructions for use in treating the skin disorder.
24. A method for treating a skin disorder in a human subject, which method comprises topically administering a topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder, wherein the composition consists essentially of 35.
(a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a hydrophilic pharmaceutically-acceptable lightly cross-linked polyacrylic acid polymer compatible with the pharmaceutical active material, (c) a pharmaceutically-acceptable base to adjust pH
(d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
25. A method of preparing a topical aqueous gel composition having a viscosity of less than about 15,000.cP and a pH of about 3 to 9 useful for treating a skin disorder in a human subject, which method comprises (a) combining water with a therapeutically-effective amount of at least one compound useful for treating such disorder and a hydrophilic pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (b) adjusting the pH to about 3 to 9, and (c) optionally combining a water-miscible solvent, and a preservative, to form the composition.
26. The method of Claim 25, wherein the compound is an antibiotic, imidazole, retinoid, corticosteroid, or a nonsteroidal anti-inflammatory drug (NSAID).
27. The method of Claim 26, wherein the compound is an antibiotic alone or in combination with a corticosteroid or a retinoid.
28. The method of Claim 27, wherein the compound is an antibiotic alone.
29. The method of Claim 28, wherein the antibiotic is clindamycin phosphate.
30. The method of Claim 29, wherein the composition has a pH of about 4 to 7, and consists essentially of 36.
48. The composition of Claim 6, wherein the corticosteroid is desonide.
49. The composition of Claim 48, wherein the desonide is present at about 0.01 % w/w to about 1.0 % w/w.
50. The method of Claim 40, wherein the corticosteroid is desonide.
51. The method of Claim 50, wherein the desonide is present at about 0.01 % w/w to about 1.0% w/w.
52. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which composition consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a hydrophilic pharmaceutically-acceptable, polymeric material compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
53. The composition of Claim 52 having a pH of about 4.0 to about 7.0, which composition consists essentially of (a) about 0.5% to about 2.0% w/w clindamycin phosphate, (b) about 0.05% to about 1.0% w/w of the polymeric material, (c) the base to adjust pH, (d) 0.0% to about 40% w/w of a water miscible solvent, (e) less than about 0.2% w/w of a preservative, and (f) purified water in a quantity sufficient to make (QSAD) 100% w/w.
54. The composition of Claim 52 having a pH of about 4 to about 7, which composition is a gel consisting essentially of (a) (i) about 0.5% to about 2% w/w clindamycin phosphate, and (ii) about 0.01% to about 0.05% w/w tretinoin;
(b) about 0.05% to about 1% w/w of the polymeric material, (c) the base to adjust pH;
(d) 0% to about 40% w/w of a water-miscible solvent;
(e) less than about 0.2% of a preservative; and (f) QSAD purified water 100% w/w.
55. A method for treating a skin disorder in a human subject, which method comprises topically administering the composition of claim 52, 53, or 54 to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder.
56. A method of preparing the composition of claim 52, 53, or 54, which method comprises (a) combining water with a therapeutically-effective amount of at least one compound useful for treating such disorder and the polymeric material, (b) adjusting the pH to about 3 to about 9, and (c) optionally combining a water-miscible solvent and a preservative to form the composition.
57. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which comprises (a) a therapeutically-effective amount of clindamycin phosphate and tretinoin useful for treating such disorder, (b) a hydrophilic pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water, wherein the clindamycin phosphate is dissolved and the tretinoin is suspended.
41.
58. The composition of Claim 57 having a pH of about 4 to about 7, which composition is a gel consisting essentially of (a) (i) about 0.5% to about 2% w/w clindamycin phosphate, and (ii) about 0.01% to about 0.05% w/w tretinoin;
(b) about 0.05% to about 1% w/w of the polymer;
(c) the base to adjust pH;
(d) 0% to about 40% w/w of a water-miscible solvent;
(e) about 0.01 to about 1% w/w of a preservative; and (f) QSAD purified water 100% w/w.
59. The composition of Claim 57 in combination with a container that accurately administers a portion of the composition for topical administration to a patient.
60. The composition of Claim 59 in combination with labeling instructions for use in treating the skin disorder.
61. A method for treating a skin disorder in a human subject, which method comprises topically administering the composition of claim 57 or 58 to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder.
62. The method of Claim 61, wherein the skin disorder is an inflammatory skin disorder, acne, or rosacea.
63. The method of Claim 62, wherein the composition is administered once a day for the period of time sufficient to improve the skin disorder.
64. The method of Claim 62, wherein the skin disorder is acne.
65. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which composition consists essentially of (a) a corticosteroid at a level of about 0.01% w/w/ to about 1% w/w, (b) a hydrophilic pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
66. The composition of Claim 65, wherein the corticosteroid is desonide at a level of about 0.05% w/w to about 0.1% w/w and the polymeric material is present at a level of about 0.05% w/w to about 1% w/w.
67. The composition of Claim 65, wherein the corticosteroid is halobetasol propionate and the polymeric material is present art a level of about 0.05%
w/w to about 1% w/w.
68. A method for treating a skin disorder in a human subject, which method comprises topically administering the composition of claim 65, 66, or 67 to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder.
69. A method of preparing the composition of claim 65, 66, or 67, which method comprises (a) combining water with a therapeutically-effective amount of the corticosteroid and the polymer, (b) adjusting the pH to about 3 to about 9, and (c) optionally combining the water-miscible solvent and the preservative to form the composition.
43.
32.
20. The composition of Claim 19 having a pH of about 4.0 to 7.0, which composition consists essentially of (a) about 0.01% to about 0.1% w/w desonide, (b) about 0.1% to about 0.4% w/w of the polymer, (d) about 3.0% to about 10% w/w of a water miscible solvent, (e) less than about 0.25% w/w of a preservative, and (f) QSAD purified water to 100% w/w.
21. The composition of Claim 19 having a pH of about 5.0 to 6.0, which composition consists essentially of:
(a) about 0.025 to about 0.05% w/w desonide, (b) about 0.3% w/w of the polymer, (c) the base to adjust pH, (d) about 5% w/w propylene glycol, (e) about 0.2 - about 0.25% w/w methylparaben and propylparaben, and (f) QSAD purified water to 100% w/w.
22. The composition of Claim 1 in combination with a container that accurately administers a portion of the composition for topical administration to a patient.
23. The composition of Claim 22 in combination with labeling instructions for use in treating the skin disorder.
24. A method for treating a skin disorder in a human subject, which method comprises topically administering a topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder, wherein the composition consists essentially of 35.
(a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a hydrophilic pharmaceutically-acceptable lightly cross-linked polyacrylic acid polymer compatible with the pharmaceutical active material, (c) a pharmaceutically-acceptable base to adjust pH
(d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
25. A method of preparing a topical aqueous gel composition having a viscosity of less than about 15,000.cP and a pH of about 3 to 9 useful for treating a skin disorder in a human subject, which method comprises (a) combining water with a therapeutically-effective amount of at least one compound useful for treating such disorder and a hydrophilic pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (b) adjusting the pH to about 3 to 9, and (c) optionally combining a water-miscible solvent, and a preservative, to form the composition.
26. The method of Claim 25, wherein the compound is an antibiotic, imidazole, retinoid, corticosteroid, or a nonsteroidal anti-inflammatory drug (NSAID).
27. The method of Claim 26, wherein the compound is an antibiotic alone or in combination with a corticosteroid or a retinoid.
28. The method of Claim 27, wherein the compound is an antibiotic alone.
29. The method of Claim 28, wherein the antibiotic is clindamycin phosphate.
30. The method of Claim 29, wherein the composition has a pH of about 4 to 7, and consists essentially of 36.
48. The composition of Claim 6, wherein the corticosteroid is desonide.
49. The composition of Claim 48, wherein the desonide is present at about 0.01 % w/w to about 1.0 % w/w.
50. The method of Claim 40, wherein the corticosteroid is desonide.
51. The method of Claim 50, wherein the desonide is present at about 0.01 % w/w to about 1.0% w/w.
52. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which composition consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a hydrophilic pharmaceutically-acceptable, polymeric material compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
53. The composition of Claim 52 having a pH of about 4.0 to about 7.0, which composition consists essentially of (a) about 0.5% to about 2.0% w/w clindamycin phosphate, (b) about 0.05% to about 1.0% w/w of the polymeric material, (c) the base to adjust pH, (d) 0.0% to about 40% w/w of a water miscible solvent, (e) less than about 0.2% w/w of a preservative, and (f) purified water in a quantity sufficient to make (QSAD) 100% w/w.
54. The composition of Claim 52 having a pH of about 4 to about 7, which composition is a gel consisting essentially of (a) (i) about 0.5% to about 2% w/w clindamycin phosphate, and (ii) about 0.01% to about 0.05% w/w tretinoin;
(b) about 0.05% to about 1% w/w of the polymeric material, (c) the base to adjust pH;
(d) 0% to about 40% w/w of a water-miscible solvent;
(e) less than about 0.2% of a preservative; and (f) QSAD purified water 100% w/w.
55. A method for treating a skin disorder in a human subject, which method comprises topically administering the composition of claim 52, 53, or 54 to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder.
56. A method of preparing the composition of claim 52, 53, or 54, which method comprises (a) combining water with a therapeutically-effective amount of at least one compound useful for treating such disorder and the polymeric material, (b) adjusting the pH to about 3 to about 9, and (c) optionally combining a water-miscible solvent and a preservative to form the composition.
57. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which comprises (a) a therapeutically-effective amount of clindamycin phosphate and tretinoin useful for treating such disorder, (b) a hydrophilic pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water, wherein the clindamycin phosphate is dissolved and the tretinoin is suspended.
41.
58. The composition of Claim 57 having a pH of about 4 to about 7, which composition is a gel consisting essentially of (a) (i) about 0.5% to about 2% w/w clindamycin phosphate, and (ii) about 0.01% to about 0.05% w/w tretinoin;
(b) about 0.05% to about 1% w/w of the polymer;
(c) the base to adjust pH;
(d) 0% to about 40% w/w of a water-miscible solvent;
(e) about 0.01 to about 1% w/w of a preservative; and (f) QSAD purified water 100% w/w.
59. The composition of Claim 57 in combination with a container that accurately administers a portion of the composition for topical administration to a patient.
60. The composition of Claim 59 in combination with labeling instructions for use in treating the skin disorder.
61. A method for treating a skin disorder in a human subject, which method comprises topically administering the composition of claim 57 or 58 to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder.
62. The method of Claim 61, wherein the skin disorder is an inflammatory skin disorder, acne, or rosacea.
63. The method of Claim 62, wherein the composition is administered once a day for the period of time sufficient to improve the skin disorder.
64. The method of Claim 62, wherein the skin disorder is acne.
65. A topical aqueous gel composition having a pH of about 3 to about 9 and a viscosity of less than about 15,000 cP for treating a skin disorder in a human subject, which composition consists essentially of (a) a corticosteroid at a level of about 0.01% w/w/ to about 1% w/w, (b) a hydrophilic pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically-acceptable base to adjust pH, (d) optionally a water miscible solvent, (e) optionally a preservative, and (f) water.
66. The composition of Claim 65, wherein the corticosteroid is desonide at a level of about 0.05% w/w to about 0.1% w/w and the polymeric material is present at a level of about 0.05% w/w to about 1% w/w.
67. The composition of Claim 65, wherein the corticosteroid is halobetasol propionate and the polymeric material is present art a level of about 0.05%
w/w to about 1% w/w.
68. A method for treating a skin disorder in a human subject, which method comprises topically administering the composition of claim 65, 66, or 67 to an affected area of the subject's skin having such disorder in an amount and for a period of time sufficient to improve the skin disorder.
69. A method of preparing the composition of claim 65, 66, or 67, which method comprises (a) combining water with a therapeutically-effective amount of the corticosteroid and the polymer, (b) adjusting the pH to about 3 to about 9, and (c) optionally combining the water-miscible solvent and the preservative to form the composition.
43.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/632,508 US6387383B1 (en) | 2000-08-03 | 2000-08-03 | Topical low-viscosity gel composition |
US09/632,508 | 2000-08-03 | ||
PCT/US2001/023341 WO2002011683A1 (en) | 2000-08-03 | 2001-07-24 | Topical gel delivery system |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2417646A1 true CA2417646A1 (en) | 2002-02-14 |
CA2417646C CA2417646C (en) | 2010-05-04 |
Family
ID=24535786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2417646A Expired - Lifetime CA2417646C (en) | 2000-08-03 | 2001-07-24 | Topical gel delivery system |
Country Status (25)
Country | Link |
---|---|
US (2) | US6387383B1 (en) |
EP (2) | EP1304992B1 (en) |
JP (1) | JP4988129B2 (en) |
KR (2) | KR20080036246A (en) |
CN (2) | CN101305982B (en) |
AR (1) | AR030093A1 (en) |
AT (1) | ATE429922T1 (en) |
AU (2) | AU7900201A (en) |
BE (1) | BE2013C060I2 (en) |
BR (1) | BR0113247A (en) |
CA (1) | CA2417646C (en) |
CY (3) | CY1109189T1 (en) |
DE (1) | DE60138549D1 (en) |
DK (2) | DK2052714T3 (en) |
ES (2) | ES2437321T3 (en) |
FR (1) | FR14C0053I1 (en) |
HK (1) | HK1125847A1 (en) |
LU (1) | LU92401I2 (en) |
MX (1) | MXPA03001006A (en) |
PL (1) | PL213237B1 (en) |
PT (2) | PT2052714E (en) |
RU (1) | RU2251410C2 (en) |
SI (2) | SI2052714T1 (en) |
WO (1) | WO2002011683A1 (en) |
ZA (1) | ZA200301037B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020097211A1 (en) * | 2018-11-06 | 2020-05-14 | Cote Tim | Topical compositions comprising pentoxifylline and methods of treatment using the same |
Families Citing this family (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
KR100638150B1 (en) | 1998-12-23 | 2006-10-26 | 이데아 악티엔게젤샤프트 | Improved formulation for topical non-invasive application in vivo |
ES2173678T3 (en) | 1999-01-27 | 2002-10-16 | Idea Ag | VACCINATION NOT INVASIVE THROUGH THE SKIN. |
SI1031347T1 (en) | 1999-01-27 | 2002-10-31 | Idea Ag | Transnasal transport/immunisation with highly adaptable carriers |
AU5409699A (en) * | 1999-07-05 | 2001-01-22 | Idea Ag | A method for the improvement of transport across adaptable semi-permeable barriers |
US6387383B1 (en) * | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
US20060189552A1 (en) * | 2000-12-12 | 2006-08-24 | Mohan Vishnupad | Dispenser for dispensing three or more actives |
US7060732B2 (en) * | 2000-12-12 | 2006-06-13 | Imaginative Research Associates, Inc. | Antibiotic/benzoyl peroxide dispenser |
IL142037A0 (en) * | 2001-03-15 | 2002-03-10 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug |
US7078048B2 (en) * | 2001-05-09 | 2006-07-18 | The Regents Of The University Of Michigan | Method and compositions for treating rosacea |
US7368122B1 (en) * | 2002-03-08 | 2008-05-06 | Dow Pharmaceutical Sciences | Skin cream |
WO2004000263A1 (en) * | 2002-06-25 | 2003-12-31 | Acrux Dds Pty Ltd | Transdermal delivery rate control using amorphous pharmaceutical compositions |
US20050186141A1 (en) * | 2002-06-25 | 2005-08-25 | Acrux Dds Pty Ltd. | Transdermal aerosol compositions |
US20050181032A1 (en) * | 2002-06-25 | 2005-08-18 | Acrux Dds Pty Ltd. | Metastable pharmaceutical compositions |
US20040171561A1 (en) * | 2002-09-03 | 2004-09-02 | Popp Karl F. | Topical formulations for treatment of rosacea |
US20040167223A1 (en) * | 2002-09-03 | 2004-08-26 | Popp Karl F. | Topical antibacterial formulations |
US6906014B2 (en) * | 2002-09-10 | 2005-06-14 | Permatex, Inc. | Stabilized topical composition |
US7473432B2 (en) * | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
US7208485B2 (en) * | 2003-01-13 | 2007-04-24 | Chemagis Ltd. | Crystalline forms of halobetasol propionate |
JP4828404B2 (en) | 2003-01-24 | 2011-11-30 | ステフェル リサーチ オーストラリア プロプライエタリー リミティッド | Clindamycin phosphate foam |
WO2004069238A1 (en) * | 2003-02-07 | 2004-08-19 | Mochida Pharmaceutical Co., Ltd. | Drug for improving prognosis for subarachnoid hemorrhage |
US20040202726A1 (en) * | 2003-04-10 | 2004-10-14 | Deshay Samuel L. | Topical blood pressure composition |
US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
TW200524927A (en) | 2003-08-12 | 2005-08-01 | 3M Innovative Properties Co | Hydroxylamine substituted imidazo-containing compounds |
AU2003265624B2 (en) * | 2003-08-21 | 2011-03-31 | Abeona Therapeutics Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
WO2005020999A1 (en) | 2003-08-27 | 2005-03-10 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
JP2007504269A (en) | 2003-09-05 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Method for treating CD5 + B cell lymphoma |
JP2007505927A (en) * | 2003-09-19 | 2007-03-15 | ドラッグテック コーポレイション | Drug delivery system |
US20060140990A1 (en) * | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
AU2003302479A1 (en) * | 2003-09-23 | 2005-04-11 | Akciju Sabiedriba "Olainfarm " | 3,5-dimethyl-1-adamantyl-ammonium polymeric salts and the use thereof in the form of antiviral agents |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
KR101154101B1 (en) | 2003-10-03 | 2012-06-11 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Alkoxy substituted imidazoquinolines |
US20050095215A1 (en) * | 2003-11-03 | 2005-05-05 | Popp Karl F. | Antimicrobial shampoo compositions |
US7897767B2 (en) | 2003-11-14 | 2011-03-01 | 3M Innovative Properties Company | Oxime substituted imidazoquinolines |
CN1906192A (en) * | 2003-11-14 | 2007-01-31 | 3M创新有限公司 | Hydroxylamine substituted imidazo ring compounds |
CA2547020C (en) | 2003-11-25 | 2014-03-25 | 3M Innovative Properties Company | 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier |
WO2005066170A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
JP5528657B2 (en) * | 2003-12-30 | 2014-06-25 | オキュラス イノヴェイティヴ サイエンシズ、インコーポレイテッド | Redox potential aqueous solution and method for producing and using the same |
EP1699788A2 (en) | 2003-12-30 | 2006-09-13 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides |
US20050139808A1 (en) * | 2003-12-30 | 2005-06-30 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and process for producing same |
US20050147570A1 (en) * | 2004-01-06 | 2005-07-07 | Nordsiek Michael T. | Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne |
TW200612932A (en) | 2004-03-24 | 2006-05-01 | 3M Innovative Properties Co | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
US20050255131A1 (en) * | 2004-05-11 | 2005-11-17 | Mohan Vishnupad | Clindamycin compositions and delivery system therefor |
US7662855B2 (en) * | 2004-05-11 | 2010-02-16 | Imaginative Research Associates, Inc. | Retinoid solutions and formulations made therefrom |
US20060014834A1 (en) * | 2004-05-11 | 2006-01-19 | Mohan Vishnupad | Retinoid solutions and formulations made therefrom |
CA2824612C (en) | 2004-05-25 | 2016-08-16 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
US8907153B2 (en) * | 2004-06-07 | 2014-12-09 | Nuvo Research Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
US8741333B2 (en) * | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
US8741332B2 (en) * | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for dermally treating neuropathic pain |
US20070196452A1 (en) * | 2004-06-07 | 2007-08-23 | Jie Zhang | Flux-enabling compositions and methods for dermal delivery of drugs |
US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
FR2887149B1 (en) * | 2005-06-17 | 2007-08-03 | Galderma Sa | PROCESS FOR SOLUBILIZING THE METRONIDAZOLE |
WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
WO2006038923A2 (en) | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
ITMI20041376A1 (en) * | 2004-07-09 | 2004-10-09 | Uni Campus Bio Medico Di Roma | METHOD OF PREPARATION OF A BIOCOMPATIBLE POLYMERIC SYSTEM FOR PHARMACOLOGICAL RELEASE IN TOPICAL USE AND USE OF THE SYSTEM |
US20060093675A1 (en) * | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
ATE467411T1 (en) * | 2004-11-09 | 2010-05-15 | Imaginative Res Associates Inc | RETINOID SOLUTIONS AND FORMULATIONS THEREOF |
JP2008519784A (en) * | 2004-11-12 | 2008-06-12 | イデア アクチェンゲゼルシャフト | Extended surface aggregates in the treatment of skin conditions |
JP5543068B2 (en) | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | Chiral fused [1,2] imidazo [4,5-c] cyclic compound |
CA2594674C (en) | 2004-12-30 | 2016-05-17 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
WO2006084251A2 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
WO2006086634A2 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
AU2006232377A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
CA2602590A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
WO2006121429A1 (en) * | 2005-05-06 | 2006-11-16 | Imaginative Research Associates, Inc. | Clindamycin compositions and delivery system therefor |
BRPI0608599A2 (en) * | 2005-05-09 | 2010-01-19 | Drugtech Corp | Modified release pharmaceutical compositions |
US8435944B2 (en) * | 2005-06-03 | 2013-05-07 | Acrux Dds Pty Ltd. | Method and composition for transdermal drug delivery |
AR054805A1 (en) * | 2005-06-29 | 2007-07-18 | Stiefel Laboratories | TOPICAL COMPOSITIONS FOR SKIN TREATMENT |
US20090117190A1 (en) * | 2005-08-23 | 2009-05-07 | Nissan Chemical Industries, Ltd. | Sustained-release preparation |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
CA2635994A1 (en) * | 2006-01-05 | 2007-07-12 | Drugtech Corporation | Drug delivery system for bioadhesion to a vulvovaginal surface |
JP2009522360A (en) * | 2006-01-05 | 2009-06-11 | ドラッグテック コーポレイション | Composition and method of use thereof |
WO2007092312A2 (en) * | 2006-02-03 | 2007-08-16 | Stiefel Laboratories, Inc. | Topical skin treating compositions |
WO2007103555A2 (en) * | 2006-03-08 | 2007-09-13 | Nuviance, Inc. | Transdermal drug delivery compositions and topical compositions for application on the skin |
EP2010133B1 (en) | 2006-03-31 | 2016-05-04 | Stiefel Research Australia Pty Ltd | Foamable suspension gel |
US20070280972A1 (en) * | 2006-04-25 | 2007-12-06 | Zars, Inc. | Adhesive solid gel-forming formulations for dermal drug delivery |
US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
CN101588791A (en) | 2006-10-17 | 2009-11-25 | 纽沃研究公司 | Diclofenac gel |
WO2008094910A2 (en) * | 2007-01-30 | 2008-08-07 | Cypress Pharmaceutical, Inc. | Hyaluronate compositions |
US20080287373A1 (en) * | 2007-05-17 | 2008-11-20 | Popp Karl F | Topical skin treating kits |
US20080312245A1 (en) * | 2007-06-12 | 2008-12-18 | Longyan Xiao | Methods and compositions for treating acne and other infectious diseases |
CA2698812A1 (en) | 2007-09-14 | 2009-03-19 | Nitto Denko Corporation | Drug carriers |
US20090098191A1 (en) * | 2007-10-16 | 2009-04-16 | Anderson Christopher G | Use of bases to stabilize transdermal formulations |
JP2011500687A (en) * | 2007-10-18 | 2011-01-06 | メディシス・ファーマシューティカル・コーポレーション | Aqueous retinoid and benzoyl peroxide gels |
US9050368B2 (en) * | 2007-11-13 | 2015-06-09 | Meritage Pharma, Inc. | Corticosteroid compositions |
US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
MX349677B (en) * | 2007-11-13 | 2017-08-08 | Meritage Pharma Inc | Corticosteroid compositions. |
US20090123551A1 (en) * | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Gastrointestinal delivery systems |
AU2008341112B2 (en) | 2007-12-21 | 2014-02-06 | Galderma S.A. | Pre-surgical treatment |
US20090176719A1 (en) * | 2008-01-07 | 2009-07-09 | Liolabs Llc | Compositions and methods for treating perioral dermatitis |
WO2009116086A2 (en) * | 2008-03-17 | 2009-09-24 | Glenmark Pharmaceuticals Limited | Stable fixed dose topical formulation |
US20090264392A1 (en) * | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
KR20110021888A (en) * | 2008-05-16 | 2011-03-04 | 갈데르마 리써어치 앤드 디벨로프먼트 | Therapy regimen for treating acne related diseases |
WO2009148584A1 (en) | 2008-06-05 | 2009-12-10 | Dow Pharmaceutical Sciences, Inc. | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
BRPI0914687A2 (en) * | 2008-06-24 | 2015-10-20 | Intervet Int Bv | spill veterinary preparation, methods for treating inflammatory conditions and for administering spill veterinary preparation, and use of spill veterinary preparation |
WO2010047831A1 (en) * | 2008-10-23 | 2010-04-29 | Nycomed Us Inc. | Stable metronidazole gel formulations |
US9775802B2 (en) | 2009-03-24 | 2017-10-03 | Bausch & Lomb Incorporated | Method for preparing suspensions of low-solubility materials |
US20100247666A1 (en) * | 2009-03-24 | 2010-09-30 | Macleod Steven K | Method for Preparing Suspensions of Low-Solubility Materials |
US8618164B2 (en) | 2009-03-31 | 2013-12-31 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
US20110097401A1 (en) * | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
US9364485B2 (en) | 2009-08-31 | 2016-06-14 | Dr. Reddy's Laboratories Ltd. | Topical formulations comprising a steroid |
EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
WO2011117377A2 (en) | 2010-03-26 | 2011-09-29 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of erythema |
ES2730411T3 (en) | 2010-03-26 | 2019-11-11 | Galderma Res & Dev | Enhanced compositions comprising brimonidine for a safe and effective treatment of telangiectasia |
CN104288768A (en) | 2010-06-30 | 2015-01-21 | 盖尔德马研究及发展公司 | Use of alpha-adrenergic receptor agonist |
US9554988B2 (en) | 2010-06-30 | 2017-01-31 | Galderma Research & Development | Method for preventing or treating skin tumor |
BR112013009578B1 (en) | 2010-10-21 | 2020-10-20 | Galderma S.A. | topical gel composition and use of a topical gel composition |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
US8809307B2 (en) | 2010-11-22 | 2014-08-19 | Dow Pharmaceutical Sciences, Inc. | Pharmaceutical formulations containing corticosteroids for topical administration |
US11957753B2 (en) | 2010-11-22 | 2024-04-16 | Bausch Health Ireland Limited | Pharmaceutical formulations containing corticosteroids for topical administration |
WO2013016072A1 (en) | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
WO2013019974A1 (en) | 2011-08-02 | 2013-02-07 | Medicis Pharmaceutical Corporation | Compositions comprising a retinoid and a lincosamide antibiotic for use in treating rosacea |
CN103889416A (en) | 2011-10-19 | 2014-06-25 | 高德美国际公司 | Method for treating capillary hemangiomas |
RU2014119879A (en) | 2011-10-19 | 2015-11-27 | Галдерма С.А. | METHOD FOR REDUCING BLOOD TIDGE TO FACE WITH SYSTEMATIC USE OF PHOSPHODESTERASE TYPE 5 INHIBITORS |
US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
UA109359C2 (en) | 2011-11-10 | 2015-08-10 | TREATMENT OF SKIN DISEASES AND STATES | |
RU2548714C2 (en) * | 2012-05-03 | 2015-04-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Pharmaceutical composition for treating acne and method for preparing it |
US8962028B2 (en) | 2012-10-18 | 2015-02-24 | MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company | Topical steroid composition and method |
RU2530644C2 (en) * | 2012-11-01 | 2014-10-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Comedolytic pharmaceutical composition and method for preparing it |
US10544405B2 (en) | 2013-01-16 | 2020-01-28 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
KR102221499B1 (en) | 2013-09-26 | 2021-03-02 | 갈데르마 소시에떼아노님 | Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring |
US20150250697A1 (en) * | 2014-03-07 | 2015-09-10 | The Procter & Gamble Company | Personal Care Compositions and Methods of Making Same |
US20160184431A1 (en) | 2014-03-11 | 2016-06-30 | Promius Pharma Llc | Topical compositions comprising a corticosteroid |
US9012402B1 (en) * | 2014-06-11 | 2015-04-21 | James Blanchard | Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation |
CN104473865A (en) * | 2014-11-17 | 2015-04-01 | 重庆华邦制药有限公司 | Desonide gel and preparation method thereof |
CA2972065A1 (en) | 2014-12-23 | 2016-06-30 | Intellectual Property Associates, Llc | Methods and formulations for transdermal administration |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
US10251895B2 (en) | 2015-06-18 | 2019-04-09 | Valeant Pharmaceuticals North America | Topical compositions and methods for treating psoriasis |
EA034808B1 (en) | 2015-07-13 | 2020-03-24 | Др. Редди'С Лабораториз Лтд. | Topical retinoid compositions |
CN106474048A (en) * | 2015-08-27 | 2017-03-08 | 重庆华邦制药有限公司 | A kind of more stable desonide gel preparation of quality |
CN106474047A (en) * | 2015-08-27 | 2017-03-08 | 重庆华邦制药有限公司 | A kind of desonide preparation stable to light |
CN106474059A (en) * | 2015-08-27 | 2017-03-08 | 重庆华邦制药有限公司 | A kind of more stable desonide lotion of quality |
US11117860B2 (en) | 2016-03-28 | 2021-09-14 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
WO2018213310A1 (en) | 2017-05-15 | 2018-11-22 | Cornell University | Device and system for repairing intervertebral disc herniation and methods of use |
US10779525B2 (en) | 2018-01-16 | 2020-09-22 | Zin Research LLC | Treatment compound and method of application for hoof or foot disease in animals |
US10653656B2 (en) * | 2018-04-05 | 2020-05-19 | Bausch Health Ireland Limited | Topical pharmaceutical compositions for treating skin conditions |
FR3090385B1 (en) * | 2018-12-21 | 2021-01-08 | Pf Medicament | Emollient composition in the form of an emulsion |
CN111743853A (en) * | 2019-03-29 | 2020-10-09 | 天津金耀集团有限公司 | External pharmaceutical composition of near-neutral hydrocortisone butyrate |
US20220040193A1 (en) | 2020-08-04 | 2022-02-10 | Venthera, Inc. | Formulations of phosphoinositide 3-kinase inhibitors |
US20220202841A1 (en) * | 2020-12-24 | 2022-06-30 | Erine A. Kupetsky | Dermatological formulations for treatment of dermatitis |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3969516A (en) | 1974-12-19 | 1976-07-13 | Nelson Research & Development Company | Composition and method for treatment of acne |
US4497794A (en) | 1980-12-08 | 1985-02-05 | Dermik Laboratories, Inc. | Erythromycin/benzoyl peroxide composition for the treatment of acne |
US4361584A (en) | 1977-10-07 | 1982-11-30 | A.H.C. Pharmacal, Inc. | Composition and method for the treatment of acne |
US4247547A (en) | 1979-03-19 | 1981-01-27 | Johnson & Johnson | Tretinoin in a gel vehicle for acne treatment |
US4387107A (en) | 1979-07-25 | 1983-06-07 | Dermik Laboratories, Inc. | Stable benzoyl peroxide composition |
US4692329A (en) | 1980-12-08 | 1987-09-08 | William H. Rorer, Inc. | Erythromycin/benzoyl peroxide antiacne compositions |
LU83173A1 (en) | 1981-02-27 | 1981-06-05 | Oreal | NOVEL COSMETIC COMPOSITIONS FOR THE TREATMENT OF HAIR AND SKIN CONTAINING POWDER RESULTING FROM THE SPRAYING OF AT LEAST ONE PLANT AND A COHESION AGENT |
US4514385A (en) | 1981-10-05 | 1985-04-30 | Alcon Laboratories, Inc. | Anti-acne compositions |
CH643138A5 (en) * | 1983-08-29 | 1984-05-30 | Mepha Ag | INDOMETHACIN CONTAINING, gelatinous OINTMENT. |
LU85111A1 (en) | 1983-12-01 | 1985-09-12 | Oreal | ANTI-ACNETIC COMPOSITION BASED ON BENZOYL PEROXIDE AND AT LEAST ONE SOLAR FILTER |
US5446028A (en) | 1985-12-12 | 1995-08-29 | Dermik Laboratories, Inc. | Anti-acne method and composition |
FR2604357B1 (en) | 1986-09-30 | 1988-12-02 | Oreal | PHARMACEUTICAL AND ANTI-ACNE COSMETIC COMPOSITION |
AU618517B2 (en) | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
ATE67667T1 (en) * | 1987-03-20 | 1991-10-15 | Curatek Pharmaceuticals | NEW TOPICAL METRONIDAZOLE FORMULATIONS. |
MY105521A (en) * | 1989-04-17 | 1994-10-31 | Healthpoint Ltd | Moisturizing vehicle for topical application of vitamin a acid. |
CA2063576C (en) | 1989-06-07 | 1994-01-25 | Gail S. Bazzano | Slow release vehicles for minimizing skin irritancy of topical compositions |
US5122519A (en) * | 1989-06-27 | 1992-06-16 | American Cyanamid Company | Stable, cosmetically acceptable topical gel formulation and method of treatment for acne |
GB9021320D0 (en) | 1990-10-01 | 1990-11-14 | Diomed Dev Ltd | Compositions for topical application |
US5380528A (en) | 1990-11-30 | 1995-01-10 | Richardson-Vicks Inc. | Silicone containing skin care compositions having improved oil control |
JP3555762B2 (en) * | 1991-10-16 | 2004-08-18 | リチャードソン、ビックス、インコーポレーテッド | Low pH aqueous cosmetic gel containing nonionic polyacrylamide derivative |
JP3190441B2 (en) * | 1992-07-20 | 2001-07-23 | エーザイ株式会社 | Stable formulation containing azelastine hydrochloride |
US5549914A (en) * | 1992-12-14 | 1996-08-27 | Sween Corporation | Heat stable wound care gel |
RO115109B1 (en) | 1993-07-01 | 1999-11-30 | Yamanouchi Europ Bv | Stable composition containing retinoid |
US5482710A (en) | 1993-07-30 | 1996-01-09 | Chesebrough-Pond'usa Co., Division Of Conopco, Inc. | Cosmetic composition for treatment of pimples and redness |
US5382432A (en) | 1993-11-15 | 1995-01-17 | Elizabeth Arden Company, Division Of Conopco, Inc. | Cosmetic method for treatment of skin |
US5466446A (en) | 1994-02-16 | 1995-11-14 | Stiefel Laboratories, Inc. | Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof |
US5538732A (en) | 1994-04-12 | 1996-07-23 | Creative Products Resource, Inc. | Medicated applicator sheet for topical drug delivery |
US5451405A (en) | 1994-04-25 | 1995-09-19 | Chesebrough-Pond's Usa Co. | Skin treatment composition |
US5445823A (en) | 1994-10-20 | 1995-08-29 | The Procter & Gamble Company | Dermatological compositions and method of treatment of skin lesions therewith |
US5562917A (en) * | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
AT408067B (en) | 1995-03-17 | 2001-08-27 | Gebro Pharma Gmbh | PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION AND METHOD FOR THE PRODUCTION THEREOF |
EP0738510A3 (en) | 1995-04-20 | 2005-12-21 | L'oreal | Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties. |
US5750122A (en) | 1996-01-16 | 1998-05-12 | The Procter & Gamble Company | Compositions for treating hair or skin |
JP3193617B2 (en) * | 1996-01-29 | 2001-07-30 | カネボウ株式会社 | Refreshing agent and composition for human body |
US5891451A (en) | 1996-06-25 | 1999-04-06 | Elizabeth Arden Company, Division Of Conopco, Inc. | Skin treatment with salicylic acid esters |
FR2753626B1 (en) * | 1996-09-20 | 1998-11-06 | Centre International De Rech Dermatologiques Galderma Cird Galderma | NOVEL TOPICAL COMPOSITIONS IN THE FORM OF A FLUID O / W EMULSION WITH A HIGH PRO-PENETRATING GLYCOL CONTENT |
JPH1179948A (en) * | 1997-09-12 | 1999-03-23 | Noevir Co Ltd | Hair tonic and hair cosmetic, and preparation for external use for skin for suppressing sebum secretion |
US6083996A (en) * | 1997-11-05 | 2000-07-04 | Nexmed Holdings, Inc. | Topical compositions for NSAI drug delivery |
US6387383B1 (en) * | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
-
2000
- 2000-08-03 US US09/632,508 patent/US6387383B1/en not_active Expired - Lifetime
-
2001
- 2001-07-24 PT PT80208200T patent/PT2052714E/en unknown
- 2001-07-24 ZA ZA200301037A patent/ZA200301037B/en unknown
- 2001-07-24 CN CN2008100852167A patent/CN101305982B/en not_active Expired - Lifetime
- 2001-07-24 MX MXPA03001006A patent/MXPA03001006A/en active IP Right Grant
- 2001-07-24 DK DK08020820.0T patent/DK2052714T3/en active
- 2001-07-24 PL PL360589A patent/PL213237B1/en unknown
- 2001-07-24 KR KR1020087008303A patent/KR20080036246A/en not_active Application Discontinuation
- 2001-07-24 WO PCT/US2001/023341 patent/WO2002011683A1/en active Application Filing
- 2001-07-24 BR BR0113247-4A patent/BR0113247A/en active IP Right Grant
- 2001-07-24 RU RU2003105831/15A patent/RU2251410C2/en active IP Right Revival
- 2001-07-24 DE DE60138549T patent/DE60138549D1/en not_active Expired - Lifetime
- 2001-07-24 KR KR1020037001564A patent/KR100840169B1/en active IP Right Grant
- 2001-07-24 CN CN018150659A patent/CN1460013B/en not_active Expired - Lifetime
- 2001-07-24 SI SI200131027T patent/SI2052714T1/en unknown
- 2001-07-24 EP EP01957238A patent/EP1304992B1/en not_active Expired - Lifetime
- 2001-07-24 ES ES08020820.0T patent/ES2437321T3/en not_active Expired - Lifetime
- 2001-07-24 AU AU7900201A patent/AU7900201A/en active Pending
- 2001-07-24 EP EP08020820.0A patent/EP2052714B1/en not_active Expired - Lifetime
- 2001-07-24 AT AT01957238T patent/ATE429922T1/en active
- 2001-07-24 CA CA2417646A patent/CA2417646C/en not_active Expired - Lifetime
- 2001-07-24 AU AU2001279002A patent/AU2001279002B2/en active Active
- 2001-07-24 ES ES01957238T patent/ES2326955T3/en not_active Expired - Lifetime
- 2001-07-24 SI SI200130926T patent/SI1304992T1/en unknown
- 2001-07-24 PT PT01957238T patent/PT1304992E/en unknown
- 2001-07-24 JP JP2002517021A patent/JP4988129B2/en not_active Expired - Lifetime
- 2001-07-24 DK DK01957238T patent/DK1304992T3/en active
- 2001-07-31 AR ARP010103660A patent/AR030093A1/en not_active Application Discontinuation
-
2002
- 2002-03-08 US US10/096,516 patent/US6517847B2/en not_active Expired - Lifetime
-
2009
- 2009-05-18 HK HK09104488.2A patent/HK1125847A1/en not_active IP Right Cessation
- 2009-06-29 CY CY20091100677T patent/CY1109189T1/en unknown
-
2013
- 2013-10-30 BE BE2013C060C patent/BE2013C060I2/nl unknown
- 2013-11-21 CY CY20131101045T patent/CY1114646T1/en unknown
-
2014
- 2014-01-23 CY CY2014005C patent/CY2014005I2/en unknown
- 2014-03-18 LU LU92401C patent/LU92401I2/en unknown
- 2014-07-04 FR FR14C0053C patent/FR14C0053I1/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020097211A1 (en) * | 2018-11-06 | 2020-05-14 | Cote Tim | Topical compositions comprising pentoxifylline and methods of treatment using the same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2417646A1 (en) | Topical gel delivery system | |
JP2004505900A5 (en) | ||
US5690923A (en) | Stable topical retinoid compositions | |
RU2003105831A (en) | LOCAL APPLICATION DELIVERY SYSTEM | |
CA2299288C (en) | Non-steroidal antiinflammatory drug formulations for topical application to the skin | |
CA2319515C (en) | Anhydrous topical skin preparations | |
US8735393B2 (en) | Anhydrous topical skin preparations | |
US5560910A (en) | Topical anti-inflammatory composition and method | |
KR101689898B1 (en) | Topical composition for the treatment of actinic keratosis | |
US20100120918A1 (en) | Novel non-aqueous topical solution of diclofenac and process for preparing the same | |
US7618651B2 (en) | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same | |
US8658678B2 (en) | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water | |
WO2015075640A1 (en) | Stable pharmaceutical formulation(s) of tetracycline antibiotic | |
BRPI0508933A (en) | compositions for topical delivery | |
KR950003919B1 (en) | Process for preparing topical metronidazole formulations | |
US8673356B2 (en) | Stable fixed dose topical formulation | |
PL207221B1 (en) | Dermatological formulations | |
US4487782A (en) | Topical treatment of non-inflammatory acne | |
HU225599B1 (en) | Thin adhesive plaster treated by betamethasone- and hyaluronic acid- for treatment of psoriasis, dermatitis and dermatosis | |
EP1765293B1 (en) | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same | |
US20010019722A1 (en) | Anti-acne chrono patch | |
US10123970B2 (en) | Topical retinoid solutions | |
US20120115954A1 (en) | Aqueous retinoid and benzoyl peroxide gel | |
JPH1029937A (en) | Pharmaceutical preparation of mefenamic acid aqueous solution | |
US4873266A (en) | Menthone enhancement of transdermal drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20210726 |